FDA-cleared profile

Aquilion Serve (TSX-307A/1) V1.2 with AiCE-i

Canon Medical Systems Corporation · CT/CTA · FDA-cleared (510(k))

Authorized purpose: The Aquilion Serve acquires and displays cross-sectional volumes of the whole body including the head, provides volume sets for specialized studies using indicated software or hardware, and includes AiCE deep-convolutional noise reduction for abdomen, pelvis, lung, cardiac, extremity, head, and inner-ear applications.

Clinical role
X-ray CT acquisition and reconstruction, with release-specific image-quality, spectral, or deep-learning processing functions where labeled.
Images and patients
CT/CTA · Whole body including head; abdomen, pelvis, lung, cardiac, extremity, and inner-ear applications for AiCE
Key limitation
Keep in mind: Use only the exact labeled scanner, software, dose, reconstruction, patient population, anatomy, and screening criteria; local dose and image-quality decisions remain clinical responsibilities.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The Aquilion Serve acquires and displays cross-sectional volumes of the whole body including the head, provides volume sets for specialized studies using indicated software or hardware, and includes AiCE deep-convolutional noise reduction for abdomen, pelvis, lung, cardiac, extremity, head, and inner-ear applications.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Whole body including head; abdomen, pelvis, lung, cardiac, extremity, and inner-ear applications for AiCE Input: X-ray transmission data acquired with the exact labeled CT system, protocols, software, and hardware.
  • Who uses it?Intended users: Qualified radiologic technologists and physicians or other trained healthcare professionals within the labeled workflow.
  • What does the software produce?Output: Cross-sectional CT images, volume sets, and labeled reconstructed or processed image outputs for professional review.
  • What is its most important limitation?Key limitation: Use only the exact labeled scanner, software, dose, reconstruction, patient population, anatomy, and screening criteria; local dose and image-quality decisions remain clinical responsibilities.

Clinical takeaway. Clinical role: The Aquilion Serve acquires and displays cross-sectional volumes of the whole body including the head, provides volume sets for specialized studies using indicated software or hardware, and includes AiCE deep-convolutional noise reduction for abdomen, pelvis, lung, cardiac, extremity, head, and inner-ear applications.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports bench testing: an image quality metric evaluation against the predicate concluded equivalent or improved performance; an AiCE image quality evaluation showed equivalent or improved performance relative to FBP and AIDR 3D; and a phantom comparison study conducted to support a claim of twice the high contrast spatial resolution for AiCE Body at 10% MTF compared to AIDR reconstruction. In clinical image review, a board-certified radiologist confirmed representative subject-device images were of diagnostic quality. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The Aquilion Serve acquires and displays cross-sectional volumes of the whole body including the head, provides volume sets for specialized studies using indicated software or hardware, and includes AiCE deep-convolutional noise reduction for abdomen, pelvis, lung, cardiac, extremity, head, and inner-ear applications.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
X-ray CT acquisition and reconstruction, with release-specific image-quality, spectral, or deep-learning processing functions where labeled.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
X-ray transmission data acquired with the exact labeled CT system, protocols, software, and hardware.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Cross-sectional CT images, volume sets, and labeled reconstructed or processed image outputs for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital, clinic, emergency, outpatient, or other labeled CT imaging environment.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified radiologic technologists and physicians or other trained healthcare professionals within the labeled workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Use only the exact labeled scanner, software, dose, reconstruction, patient population, anatomy, and screening criteria; local dose and image-quality decisions remain clinical responsibilities.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports bench testing: an image quality metric evaluation against the predicate concluded equivalent or improved performance; an AiCE image quality evaluation showed equivalent or improved performance relative to FBP and AIDR 3D; and a phantom comparison study conducted to support a claim of twice the high contrast spatial resolution for AiCE Body at 10% MTF compared to AIDR reconstruction. In clinical image review, a board-certified radiologist confirmed representative subject-device images were of diagnostic quality. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Performance Testing - Bench Objective IQ Performance Comparison An image quality metric evaluation comparing performance of the TSX-307A (Aquilion Serve) system relative to the predicate device was conducted." … "It was concluded that the subject device demonstrated equivalent or improved performance, compared to the predicate device, as demonstrated by the results of the above testing.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports bench testing: an image quality metric evaluation against the predicate concluded equivalent or improved performance; an AiCE image quality evaluation showed equivalent or improved performance relative to FBP and AIDR 3D; and a phantom comparison study conducted to support a claim of twice the high contrast spatial resolution for AiCE Body at 10% MTF compared to AIDR reconstruction. In clinical image review, a board-certified radiologist confirmed representative subject-device images were of diagnostic quality. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Performance Testing - Bench Objective IQ Performance Comparison An image quality metric evaluation comparing performance of the TSX-307A (Aquilion Serve) system relative to the predicate device was conducted." … "It was concluded that the subject device demonstrated equivalent or improved performance, compared to the predicate device, as demonstrated by the results of the above testing.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for K222819

  • DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K222819; this is regulatory evidence, not an independent clinical effectiveness study.
  • PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K222819; a broader clinical population is not established here.
  • Scopeexact submission
  • Tested versionAquilion Serve (TSX-307A/1) V1.2 with AiCE-i (K222819)
  • IndependenceSponsor or vendor study

K222819

The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: X-ray transmission data acquired with the exact labeled CT system, protocols, software, and hardware.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K222819: Aquilion Serve (TSX-307A/1) V1.2 with AiCE-i

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Exact FDA evidence does not establish the complete local interface, identity, routing, display, report, fallback, or interoperability behavior for this submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Cross-sectional CT images, volume sets, and labeled reconstructed or processed image outputs for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K222819: Aquilion Serve (TSX-307A/1) V1.2 with AiCE-i

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional CT images, volume sets, and labeled reconstructed or processed image outputs for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K222819: Aquilion Serve (TSX-307A/1) V1.2 with AiCE-i

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Security
Canon Medical's cybersecurity page states that Canon imaging systems follow a software development life cycle governed by the NIST 800-53 Risk Management Framework adhering to Defense Health Agency certification requirements; FIPS 140-2 certified cipher standards; deny-all firewall configuration and near-real-time SIEM syslog export as premium offerings; a dedicated cybersecurity risk management team for threat intelligence monitoring, advisories and incident response; and published OS and third-party update policies. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the page is on us.medical.canon, Canon Medical's own site (Canon Medical Systems USA), and describes Canon Medical imaging devices generally; the FDA applicant is Canon Medical Systems Corporation, named in the corporate name-change press release on the same domain. Regional page with general device claims; exact-release scope is not established.

Workflow role

X-ray CT acquisition and reconstruction, with release-specific image-quality, spectral, or deep-learning processing functions where labeled.

exact submission · checked 2026-09-04

Submission-anchored workflow summary, not a local acceptance or deployment result.

Input

X-ray transmission data acquired with the exact labeled CT system, protocols, software, and hardware.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Cross-sectional CT images, volume sets, and labeled reconstructed or processed image outputs for professional review.

exact submission · checked 2026-09-04

Output review, editing, approval, export, and downstream use remain release- and site-specific.

Deployment evidence

Exact deployment topology and operational boundaries remain unestablished.

exact submission · checked 2026-09-04

Confirm hosting, PHI flow, retention, access, updates, downtime, and support obligations before procurement or clinical use.

Integration evidence

Exact local interfaces, identity matching, routing, display, reporting, and fallback behavior remain unestablished.

exact submission · checked 2026-09-04

Validate the local workflow against the exact release and enabled options.

Vendor family context

Current vendor material is product-family context for K222819 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K222819
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Whole body including head; abdomen, pelvis, lung, cardiac, extremity, and inner-ear applications for AiCE
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-03-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not applicable - checked 2026-09-04 - Not applicable

    CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.

  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Exact FDA evidence does not establish the complete local interface, identity, routing, display, report, fallback, or interoperability behavior for this submission.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K222819: Aquilion Serve (TSX-307A/1) V1.2 with AiCE-i

    U.S. Food and Drug Administration - Published 2023-03-03 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Canon Medical CT family context

    Canon Medical Systems - Accessed 2026-09-04

    Scope: productFamilyContext

  8. Canon Medical: Medical Imaging Cybersecurity

    Canon Medical Systems USA - Accessed 2026-10-26

    Scope: security

Research history

  1. K222819 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K233334

Aquilion Serve SP (TSX-307B/1) V1.3

Canon Medical Systems Corporation

Authorized purpose: The Aquilion Serve SP (TSX-307B/1) V1.3 acquires and displays cross-sectional volumes of the whole body including the head, provides volume sets for specialized studies using indicated software or hardware, and includes AiCE deep-convolutional noise reduction for abdomen, pelvis, lung, cardiac, extremity, head, and inner-ear applications.

Modality
CT/CTA
Anatomy
Whole body including head; abdomen, pelvis, lung, cardiac, extremity, and inner-ear applications for AiCE
Decision
2023-12-06
FDA-cleared K231281

Aquilion Serve (TSX-307A/1) V1.3

Canon Medical Systems Corporation

Authorized purpose: The Aquilion Serve acquires and displays cross-sectional volumes of the whole body including the head, provides volume sets for specialized studies using indicated software or hardware, and includes AiCE deep-convolutional noise reduction for abdomen, pelvis, lung, cardiac, extremity, head, and inner-ear applications.

Modality
CT/CTA
Anatomy
Whole body including head; abdomen, pelvis, lung, cardiac, extremity, and inner-ear applications for AiCE
Decision
2023-09-19
FDA-cleared K253786

syngo.CT Coronary Cockpit

Siemens Medical Solutions USA, Inc.

Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-06-25

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history